Vimarsana
Biggest News Aggregation in the World

Page 29 - Updated March News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Updated March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Updated March Today - Breaking & Trending Today

Description of the Small Business Investment Company Debenture Program — Updated October 2023 | Troutman Pepper - Vimarsana News

Description of the Small Business Investment Company Debenture Program — Updated October 2023 | Troutman Pepper

The SBIC Program - A Small Business Investment Company (SBIC) is a privately owned and operated company that makes long-term investments in American small businesses and...

BLA Resubmitted to FDA for On-Body Injector Presentation of Pegfilgrastim-cbqv - Vimarsana News

BLA Resubmitted to FDA for On-Body Injector Presentation of Pegfilgrastim-cbqv

The biologics license application seeking the approval of the on-body injector presentation of pegfilgrastim-cbqv, a biosimilar of pegfilgrastim, has been resubmitted to the FDA for review.

Breast Cancer Symptoms By Stage (1-4) - Vimarsana News

Breast Cancer Symptoms By Stage (1-4)

How is breast cancer staged, what are breast cancer symptoms as malignancy progresses, and how do its effects differ by stage?

FDA Issues CRL to BLA for On-Body Injector Presentation of Pegfilgrastim-cbqv - Vimarsana News

FDA Issues CRL to BLA for On-Body Injector Presentation of Pegfilgrastim-cbqv

The FDA has issued a complete response letter to the biologics license application seeking the approval of the on-body injector presentation of pegfilgrastim-cbqv, which is a biosimilar of pegfilgrastim.

Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML - Vimarsana News

Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML

Positive opinion based on QuANTUM-First results demonstrating quizartinib combined with standard chemotherapy improved overall survival ...